Sagent Pharmaceuticals launches Ketorolac Tromethamine Injection, USP
According to IMS, for the 12 months ending July 2014, the US market for Ketorolac approximated $34 million. As with all products in Sagent’s portfolio, Ketorolac features Sagent’s
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
A statistically significant and clinically relevant response was seen in a prospectively-identified, substantial sub-group of patients with moderate to severe pain who had relatively intact sensory responses as
Odanacatib, which is firm’s investigational once-weekly cathepsin K inhibitor, has reached the primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with
The AZD3293 is an oral beta secretase cleaving enzyme (BACE) inhibitor, which significantly reduced amyloid beta levels in the cerebro-spinal fluid of Alzheimer’s patients and healthy volunteers in
The first of these agreements is a joint development program with St. Jude Children’s Research Hospital (Memphis, Tennessee, United States, "St. Jude") and the non-profit public-private partnership Medicines